ATRC
AtriCure, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 12 ▼ 1 insider sell $149.2K at $29.83
- May 15 to May 20 ▼ 2 days of insider sells: $226.6K by 2 insiders, avg $28.33
- Jul 28 to Aug 5 ▼ 3 days of insider sells: $1.7M by 5 insiders, avg $38.24
- Aug 24 ▼ 1 insider sell $458.1K at $48.89
- Sep 2 to Sep 11 ▼ 3 days of insider sells: $896.8K by 2 insiders, avg $53.59
- Sep 23 ▼ 1 insider sell $271.1K at $60.00
- Sep 29 ▼ Gilbert Cisneros sold $1,001 - $15,000, last disclosed Oct 13
- Sep 30 ▲ 3 funds open new positions (13F)
- Oct 2 ▼ Freedom Capital Markets downgrades
- Nov 3 ▲ AtriCure reported Q3 2026 revenue of $154.5M (+15.0% YoY), beating t…
- Nov 3 ▲ Earnings: ATRC Q3 2026 Earnings: EPS $0.17 (+426.3% vs est)
- Nov 4 to Nov 6 ▼ 2 days of insider sells: $689.7K by 2 insiders, avg $63.53
Signal stack
Where each data set points today.
- InsidersBEARISH
9 insiders sold $4.4M.
- InstitutionsMIXED
Q3 2026: 28 added (3 new), 22 trimmed or exited. Largest new: Loomis Sayles & L P $17.6M, Public Sector Pension Investment Board $14.8M.
- AnalystsBULLISH
11 of 15 rate it Buy or better. Median target $68.00 (+23%).
- EstimatesFALLING
Current-quarter EPS estimate $0.088 → $0.068 over 90 days. 3 up, 3 down in 30 days.
- Short sellersSTEADY
Short interest +0.1% to 4.89M shares. 7.6 days to cover, ≈9.6% of shares.
- TrendRANGE
4% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $446.4M |
| STATE STREET CORP | ADD | $119.6M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | $52.8M |
| PRINCIPAL FINANCIAL GROUP INC | DOUBLED | $21.7M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $18.0M |
| LOOMIS SAYLES & CO L P | NEW | $17.6M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | NEW | $14.8M |
| Invesco Ltd. | DOUBLED | $14.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analystsPrice is inside the target range. Median implies +23%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 4, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 4, 2026 | JP Morgan MAINTAIN | Neutral |
| Nov 4, 2026 | Piper Sandler REITERATE | Overweight |
| Nov 4, 2026 | Needham MAINTAIN | Buy |
| Nov 4, 2026 | BTIG MAINTAIN | Buy |
| Oct 21, 2026 | Citizens MAINTAIN | Market Outperform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
JOHNSON B KRISTINE Director Nov 6, 2026 | SELL | $143.4K |
Privitera Salvatore Chief Technical Officer Nov 4, 2026 | SELL | $546.3K |
Privitera Salvatore Chief Technical Officer Sep 23, 2026 | SELL | $271.1K |
GROVES REGINA E Director Sep 11, 2026 | SELL | $288.1K |
Privitera Salvatore Chief Technical Officer Sep 8, 2026 | SELL | $201.1K |
Privitera Salvatore Chief Technical Officer Sep 2, 2026 | SELL | $407.6K |
Dahlquist Karl S. Chief Legal Officer Aug 24, 2026 | SELL | $458.1K |
Prange Karen Director Aug 5, 2026 | SELL | $138.3K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.07 | $0.04–$0.10 | -22.1% | $159.5M |
| Next Q | $0.03 | -$0.05–$0.11 | +1051.1% | $158.6M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
19 filings · 4 bullish · 1 bearish · 2 mixed · 12 neutral- MIXED INST-CLUSTERNov 16, 2026
In Q2 2026, 34 institutional investors accumulated $44.0M in AtriCure shares (net +$28.8M), while 14 reduced holdings by $46.5M, resulting in a net selling quarter of $17.7M. The buying was concentrated among quant and active managers (Point72 new $16.9M, D.E.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Wellington Management Group LLP filed an amended Schedule 13G disclosing a 8.1% passive stake in AtriCure as of September 30, 2026, up from a prior filing that showed a smaller position. The increase is routine for a passive investment manager and does not signal activist intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL CLUSTERNov 10, 2026
Two AtriCure insiders sold a combined $690K in open-market sales within a week of the company's…
The dollar amount is too small relative to market cap to signal a material change in insider sentiment. The CTO's sale under a 10b5-1 plan is routine. Monitor next Form 4 filings for any larger or…
- NEUTRAL 144Nov 6, 2026
Director B. Kristine Johnson (via her trust) filed a Form 144 notice to sell 2,452 shares of…
The filing is a routine advance notice of a small sale by a director. The shares were acquired over five years ago via vesting, suggesting a standard portfolio rebalancing. No material read-through…
All ATRC filing & press-release reports (19)
- INST-CLUSTER reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- CLUSTER reportNov 10, 2026
- 144 reportNov 6, 2026
- INST-CLUSTER reportNov 6, 2026
- 144 reportNov 4, 2026
- 8-K reportNov 3, 2026
- SC 13G/A reportOct 30, 2026
- SC 13G/A reportOct 5, 2026
- CLUSTER reportSep 14, 2026
- CLUSTER reportAug 7, 2026
- CLUSTER reportJul 30, 2026
- CLUSTER reportJul 30, 2026
- 8-K reportJul 23, 2026
- INST-CLUSTER reportJun 14, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportMay 22, 2026
- 8-K reportMay 5, 2026
- DEFA14A reportApr 6, 2026